Clinical Trial

Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer

Study acronym: SERENA-1b
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A study to investigate camizestrant in combination with atirmociclib in participants with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer previously treated with a cyclin dependent kinase 4/6 (CDK4/6) inhibitor.
Protocol Amendment History 1 change
critical Recruitment opened 2026-05-29
Trial Details
NCT Number NCT07427394
Lead Sponsor AstraZeneca
Conditions Advanced Breast Cancer
Enrollment 24 participants
Start Date 2026-05-06
Primary Completion 2027-12-29 (estimated)
Study Completion 2027-12-29 (estimated)
Updated on ClinicalTrials.gov 2026-08-07